Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Kyverna Therapeutics Inc. (KYTX) stock has reached a new 52-week low, trading at $2.78, down 10.4% in the past week alone, as the biotechnology firm faces a challenging market environment. According ...

Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...

The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. . Shareholders who purchased shares ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. pursuant and/or traceable to Kyverna's initial public offering conducted on ...

The complaint filed alleges that, pursuant and/or traceable to the Registration Statement issued in connection with the Company's February 2024 initial public offering, Defendants failed to ...